



FOR IMMEDIATE RELEASE

**Sun Pharma announces distribution alliance with
 Mitsubishi Tanabe Pharma Corporation in Japan**

Transfer process of marketing authorizations for 14 Rx brands to begin in October

MUMBAI & TOKYO - SEPTEMBER 06, 2016: Sun Pharma (*Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies*) today announced the initiation of a phased transfer of manufacturing & marketing rights in Japan for the 14 long-listed/established prescription brands acquired from Novartis. These 14 prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma K.K. to Sun Pharma's subsidiary in Japan beginning October 2016.

Sun Pharma has also signed a strategic distribution alliance with Mitsubishi Tanabe Pharma Corporation for these 14 prescription brands. Under this alliance, following the transfer of manufacturing & marketing rights to Sun Pharma's subsidiary in Japan, Mitsubishi Tanabe Pharma Corporation will market and distribute all the 14 brands as well as provide information on their proper use to healthcare professionals.

According to Isao Muramatsu, President & Representative Director, Sun Pharma Japan Ltd, Sun Pharma, *"Through this alliance we have the opportunity to leverage Mitsubishi Tanabe Pharma Corporation's specialized expertise to create a strong business foundation for us in Japan. Sun Pharma will focus on expanding its sales channels in Japan's pharmaceutical market while continuing to ensure a stable supply of medicines and healthcare information."*

The schedule of transfer of these 14 brands is given below:

Date of Transfer: October 20, 2016

Brand name	Generic name	Major indications	Scheduled date of sale
Parlodel®	Bromocriptine mesylate	Parkinson's syndrome	November 1, 2016
Lamisil®	Terbinafine	Tinea unguium, tinea manuum and pedis, candidiasis	
Nitroderm®	Nitroglycerin	Angina pectoris	November 21, 2016

Date of Transfer: November 21, 2016

Brand name	Generic name	Major indications	Scheduled date of sale
Apresoline®	Hydralazine hydrochloride	Essential hypertension	December 1, 2016
Zaditen®	Ketotifen fumarate	Allergic rhinitis	
Symmetrel®	Amantadine hydrochloride	Parkinson's syndrome	
Cibacen®	Benazepril hydrochloride	Hypertension	
Tegretol®	Carbamazepine	Epilepsy	

Sun Pharmaceutical Industries Ltd
 Sun House, CTS No. 201 B/1,
 Western Express Highway,
 Goregaon (E), Mumbai 400063, India.
 CIN: L24230GJ1993PLC019050
 www.sunpharma.com



Pursennid®	Sennosides A and B	Constipation	
Lioresal®	Baclofen	Spastic paralysis associated with cerebrovascular disorder	
Lopresor®	Metoprolol tartrate	Angina pectoris, achyarrhythmia	

Scheduled transfers in 2017

Brand name	Generic name	Major indications	Scheduled date of sale
Ternelin™	Tizanidine hydrochloride	Neck, lumbago Shoulder and arm Syndrome	2017
Ludiomil®	Maprotiline hydrochloride	Depression	
Lochol®	Fluvastatin sodium	Hypercholesterolemia	

About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 47 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The consolidated revenues for 12 months ending March 2016 are approximately US\$ 4.3 billion, of which US contributes US\$ 2.1 billion. In India, the company enjoys leadership across 12 different classes of doctors with 32 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 8% of annual revenues.

For further information please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live

Safe Harbor: All forward-looking statements in this press release involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by such statements. Sun Pharma does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

For Further Information Please Contact

Sun Pharma Corporate Communications:

Frederick Castro | +91 9920665176 | frederick.castro@sunpharma.com

Sun Pharma Investor Relations:

Nimish Desai | +91 9820330182 | nimish.desai@sunpharma.com

Sun Pharma Japan Contact:

Hikohito Fujinawa | TEL 03-6432-4921